My take on $AGRX is the only thing you have to be concerned about is an offering for the meantime. (Even though they have cash into 2020). Brudac vote is extrememly bullish if you look back to similar votes by Brudac;Amgen’s Evenity Romosozumab 18-1 That being said FDA approval didn’t come until 3 months later Please let me know if you agree of disagree with this DD. Open for challenge
  • 2
  • 3